SELLAS AML Readout Two Events Away as Retail Bets Surge
SELLAS Life Sciences is two death events away from final analysis on its Phase 3 AML trial, the sole catalyst for the stock. While retail investors bid the stock 5% higher on a LinkedIn post with no c
SELLAS AML Readout Two Events Away as Retail Bets Surge
NEW YORK, October 20 —
A LinkedIn anniversary post from the CEO of SELLAS Life Sciences Group, Inc. (SLS), no trial data, no timeline, no new clinical information, drove the stock up 5% on October 19, to $10.49, while retail investors on Stocktwits floated buyout valuations between $40 billion and $120 billion. The company's Phase 3 AML trial is two death events from its prespecified final-analysis trigger.
- Phase 3 Regal trial: 78 of 80 required death events reached as of May 11, 2026, final analysis can be triggered at any time.
- $140M cash, zero debt, $28M annual operating cash burn, roughly five years of runway at current spend.
- 27.4% of float sold short; analyst consensus price target of $32.50 vs. current $11.54.
The Anniversary Post That Moved Nothing, and Then the Stock
SELLAS, a 13-person late-stage biopharmaceutical company, develops galinpepimut-S (GPS), a peptide immunotherapy targeting the WT1 antigen expressed across multiple cancers, alongside SLS009 (tambiciclib), a CDK9 inhibitor. CEO Angelos Stergiou's October 19 LinkedIn post marking the company's 15th anniversary described the GPS and SLS009 programs and referenced a "next chapter," but disclosed nothing new on clinical timelines or data readouts. The 90% spike in Stocktwits message volume and retail price targets ranging from $100 to $540 that followed represent sentiment, not signal, a distinction the 27.4% short interest suggests at least part of the market is drawing clearly.
Two Deaths From a Binary
The math inside the Regal Phase 3 trial is the only number that matters here. With 78 of the required 80 death events recorded as of May 11, the final-analysis trigger could fire at any moment, collapsing an option into an outcome. SELLAS holds a collaboration with Merck to evaluate GPS alongside Keytruda across up to five cancer indications; a positive AML readout would validate that partnership's strategic logic. A negative one would land against a $2.33 billion market cap supported by no product revenue and $28 million in annual operating cash outflow. The short position is not a mystery, it is a bet on that second scenario. See the full DCF model and price target →
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| SLS | $2.3B | n/a | +449.2% |
| GLSI | $239M | n/a | +66.0% |
| IMMP | $23M | n/a | -92.3% |
| VTVT | $110M | n/a | +28.3% |
| IBRX | $9.4B | n/a | +245.1% |
| CAPR | $393M | n/a | +4.4% |
What Resolves the Trade
The Regal readout is the sole near-term checkpoint. SLS009 is drawing attention on what retail-focused reports have described as bullish pancreatic cancer data, but that program is earlier-stage and does not alter the binary setup. Institutional investors hold 37% of shares against 0.9% insider ownership, a structure that leaves the stock unusually exposed to retail momentum. A positive AML efficacy signal would break the bearish thesis; a trial failure would confirm it. Everything else, including anniversary posts and speculative buyout math, is noise ahead of that single readout. See SELLAS Life Sciences Group, Inc.'s latest numbers for current data.
Current fundamentals, valuation and filing history for SELLAS Life Sciences Group, Inc. (SLS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
When will SELLAS announce its AML trial results?
SELLAS' Phase 3 Regal trial has recorded 78 of the required 80 death events as of May 11, 2026, meaning the final-analysis trigger could fire at any moment. This trial readout is the sole near-term checkpoint for investors.
Why did SELLAS stock jump on October 19?
CEO Angelos Stergiou posted a LinkedIn message marking the company's 15th anniversary that disclosed no new clinical data or timelines. The post drove a 5% stock gain to $10.49 and sparked retail speculation on Stocktwits with buyout valuations between $40 billion and $120 billion.
What is SELLAS Life Sciences developing?
SELLAS develops galinpepimut-S (GPS), a peptide immunotherapy targeting the WT1 antigen across multiple cancers, and SLS009 (tambiciclib), a CDK9 inhibitor. The company also holds a collaboration with Merck to evaluate GPS alongside Keytruda.
How much short interest does SELLAS have?
SELLAS has 27.4% of its float sold short. The company holds $140 million in cash, zero debt, and $28 million in annual operating cash burn, providing roughly five years of runway at current spending levels.
Is SELLAS Life Sciences profitable?
SELLAS has no product revenue and burns $28 million annually in operating cash. The Phase 3 Regal trial readout is the sole near-term checkpoint for the company.
SELLAS Life Sciences stock jumped 5% after CEO Angelos Stergiou posted a LinkedIn anniversary message containing no trial data and no clinical timeline, while retail investors floated $40 billion to $120 billion buyout scenarios — all as the company's Phase 3 AML trial sits just two death events away from its prespecified final-analysis trigger.